At TatvaCare, we are dedicated to validating the impact of our digital therapeutics on patient health through rigorous clinical trials, we test and refine our solutions, ensuring they meet the highest standards of efficacy and safety.
Each study is designed to produce measurable, scientifically-backed results that support better health outcomes for chronic conditions such as Diabetes, Obesity, COPD, and more
Digital therapeutics provide innovative solutions for chronic conditions, but their potential must be validated with robust evidence. At TatvaCare, we conduct these trials not just to prove efficacy and safety but to refine and optimize our MyTatva care programs.
These studies allow us to:
Every trial reflects our dedication to improving lives through digital, patient-centric solutions.
Our trials are not just about data; they are about advancing the care journey for every MyTatva user. Here’s how we ensure excellence in our process:
Each trial is guided by a detailed protocol that outlines objectives, methods, and assessment criteria.
We select participants who represent real-world users of MyTatva. This diversity helps us refine personalized care plans, ensuring they are effective across varying demographics and health conditions.
Our digital therapeutic interventions, tailored to each participant, include personalized diet and exercise plans, virtual consultations with our in-house healthcare professionals, and access to real-time support.
We use both patient-reported outcomes and data from wearables (like smartwatches and BCA devices) to gather objective and reliable health data.
Health metrics and vitals are tracked over time to evaluate the impact of interventions. Statistical analysis helps us interpret results and verify clinical benefits.
At TatvaCare, our commitment to ethics and safety drives every clinical trial. We adhere to national and international research standards, ensuring patient privacy and data security. Each trial is reviewed by institutional ethics committees to maintain the integrity of our research and the trust of our participants.
Our clinical trials are designed to prioritize patient comfort, convenience, and transparency. Here’s how we support our participants:
We ensure that all participants fully understand the study details, including potential benefits, risks, and their rights. Each participant is guided through the consent process before beginning the trial.
Participants have access to ongoing support through virtual consultations with TatvaCare’s in-house team, regular check-ins, and progress tracking.
The MyTatva app and integrated wearable devices make health management easy and engaging. Participants can track their own progress and stay informed about their health improvements, fostering a sense of achievement and motivation.
Our clinical trials go beyond validation—they pave the way for the future of healthcare. MyTatva programs are designed to create a paradigm shift in chronic and metabolic condition management, empowering patients to take charge of their health.
Through continuous research and innovation, we aim to integrate digital therapeutics into mainstream care, making personalized health management accessible to all. Our trials are a testament to our unwavering commitment to improving patient lives through science and technology.
| Product (Code) | Indication | Discovery | Development | Study | Publication |
|---|---|---|---|---|---|
| RESET (MyT001) | Non Alcoholic Fatty Liver Disease (NAFLD) |
|
|||
| GLIDE (MyT002) | Diabetes |
|
|||
| BREATHE (MyT003) | Chronic Obstructive Pulmonary Disease (COPD) |
|
|||
| MyT004 | Metabolic Disorder |
|
|||
| MyT005 | Hypertension |
|
|||
| MyT006 | Dyslipidemia |
|
|||
| MyT007 | Congestive Heart Failure (CHF) |
|
|||
| MyT008 | Uterine Fibroid |
|
|||
| MyT009 | Breast Cancer |
|
|||
| MyT010 | Obesity |
|
|||
| MyT011 | Polycystic Ovary Syndrome (PCOS) |
|
|||
| MyT012 | Prostate Cancer |
|
|||
| MyT013 | Male sexual wellness |
|
|||
| MyT014 | Woman health |
|
|||
| MyT015 | Endometriosis |
|
|||
To understand the impact of lifestyle modification in diet and exercise delivered by MyTatva application in the management of patients with COPD.
11 Sites
50 Participants
12 weeks
Adults over 40 with moderate to severe COPD, FEV1 between 40% and 80%, no exacerbations in the past 12 months.
To assess the impact of lifestyle modifications, including diet, exercise, and Cognitive Behavioural Therapy (CBT), delivered by the MyTatva application in managing patients with Non-alcoholic Fatty Liver Disease (NAFLD).
3 Sites
22 Participants
12 weeks
Patients with NAFLD, BMI between 25 kg/m² and 40 kg/m², willing to use digital health tools
Weight: Mean reduction of 6.99 kg
BMI: Mean reduction of 2.18 kg/m²
Muscle Mass: Mean reduction of 0.72 kg
Subcutaneous Fat: Mean reduction of 1.26%
Visceral Fat: Mean reduction of 2.16%
To assess the impact of lifestyle modifications, including diet, exercise, and Cognitive Behavioural Therapy (CBT), delivered by the MyTatva application in managing patients with Non-alcoholic Fatty Liver Disease (NAFLD).
1 Site
27 Participants
12 weeks
Patients with Type 2 Diabetes Mellitus (T2DM), HbA1c >6.5%, aged 18 or older
HbA1c Reduction: Reduced by an average of 0.99%
Fasting Blood Sugar: Decreased by an average of 54.46 mg/dL
Postprandial Blood Sugar: Decreased by 124.62 mg/dL
Total Cholesterol: mean reduction of 2.07 mg/dL
Weight: mean reduction of 2.84 kg
BMI: mean decrease of 1.21 kg/m²
Body Fat Percentage: mean reduction of 1.37%
Triglycerides: mean reduction of 1.3 mg/dL
